Rice Hall James & Associates LLC Takes $554,000 Position in Corteva, Inc. $CTVA

Rice Hall James & Associates LLC acquired a new position in shares of Corteva, Inc. (NYSE:CTVA) during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 6,622 shares of the company’s stock, valued at approximately $554,000.

Several other institutional investors also recently made changes to their positions in the stock. William B. Walkup & Associates Inc. grew its position in Corteva by 2.9% during the first quarter. William B. Walkup & Associates Inc. now owns 4,457 shares of the company’s stock worth $373,000 after buying an additional 126 shares during the period. Wilkerson Advisory Group LLC lifted its position in shares of Corteva by 6.7% during the 1st quarter. Wilkerson Advisory Group LLC now owns 2,112 shares of the company’s stock valued at $177,000 after acquiring an additional 133 shares during the period. AdvisorNet Financial Inc boosted its stake in shares of Corteva by 2.4% during the 1st quarter. AdvisorNet Financial Inc now owns 5,694 shares of the company’s stock worth $477,000 after acquiring an additional 135 shares in the last quarter. First Horizon Corp grew its holdings in shares of Corteva by 9.2% in the 1st quarter. First Horizon Corp now owns 1,600 shares of the company’s stock worth $134,000 after acquiring an additional 135 shares during the period. Finally, Aviance Capital Partners LLC increased its stake in Corteva by 1.3% in the 1st quarter. Aviance Capital Partners LLC now owns 11,008 shares of the company’s stock valued at $922,000 after purchasing an additional 137 shares in the last quarter. 81.54% of the stock is currently owned by hedge funds and other institutional investors.

Key Stories Impacting Corteva

Here are the key news stories impacting Corteva this week:

• Positive Sentiment: Oppenheimer raised its price target on Corteva to $95 from $89 and kept an “outperform” rating, signaling confidence in further upside for the stock.
• Positive Sentiment: Zacks upgraded Corteva to Rank #2 (Buy), citing improving earnings prospects ahead of the company’s upcoming results.
• Positive Sentiment: Analysts expect Q2 earnings growth as premium seed demand, new products, and productivity gains help offset pricing and inflation pressure. Corteva Set to Report Q2 Earnings: What Investors Should Expect
• Neutral Sentiment: Corteva declared a quarterly dividend of $0.18 per share, payable September 15 to shareholders of record on September 1, which supports the stock’s income profile but is not a major growth catalyst. Corteva Declares Quarterly Dividend
• Neutral Sentiment: The company is set to report Q2 earnings soon, and investors are awaiting confirmation that demand and operating efficiency trends are holding up. Corteva (CTVA) Projected to Release Quarterly Earnings on Thursday

Analyst Upgrades and Downgrades

Several research firms recently commented on CTVA. BNP Paribas Exane boosted their price objective on shares of Corteva from $74.00 to $77.00 in a research report on Wednesday, May 6th. The Goldman Sachs Group lifted their target price on shares of Corteva from $88.00 to $96.00 and gave the stock a “buy” rating in a research report on Tuesday, April 14th. Argus upped their price target on shares of Corteva from $80.00 to $91.00 and gave the company a “buy” rating in a report on Tuesday, March 31st. Jefferies Financial Group increased their price target on shares of Corteva from $95.00 to $97.00 in a research report on Thursday, May 7th. Finally, Bank of America raised their price objective on shares of Corteva from $90.00 to $96.00 and gave the stock a “buy” rating in a research note on Monday, July 20th. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating and eight have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $90.19.

Corteva Price Performance

Shares of NYSE CTVA opened at $89.23 on Monday. The company has a debt-to-equity ratio of 0.07, a current ratio of 1.47 and a quick ratio of 1.03. Corteva, Inc. has a 1-year low of $60.53 and a 1-year high of $89.39. The company has a market capitalization of $59.68 billion, a price-to-earnings ratio of 52.49, a PEG ratio of 2.70 and a beta of 0.56. The business has a 50-day moving average of $81.39 and a 200-day moving average of $78.99.

Corteva (NYSE:CTVA) last issued its quarterly earnings data on Tuesday, May 5th. The company reported $1.50 earnings per share for the quarter, beating analysts’ consensus estimates of $1.18 by $0.32. The firm had revenue of $4.91 billion during the quarter, compared to analyst estimates of $4.64 billion. Corteva had a return on equity of 9.95% and a net margin of 6.50%.Corteva’s quarterly revenue was up 11.0% on a year-over-year basis. During the same quarter last year, the firm earned $1.13 EPS. Corteva has set its FY 2026 guidance at 3.450-3.700 EPS. On average, equities analysts anticipate that Corteva, Inc. will post 3.76 EPS for the current fiscal year.

Corteva Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, September 15th. Shareholders of record on Tuesday, September 1st will be paid a $0.18 dividend. This represents a $0.72 dividend on an annualized basis and a yield of 0.8%. The ex-dividend date is Tuesday, September 1st. Corteva’s dividend payout ratio (DPR) is presently 42.35%.

Corteva Profile

Corteva, Inc (NYSE: CTVA) is an independent global agriculture company that was established as a publicly traded firm in mid‑2019 following the separation of the agriculture businesses from DowDuPont. The company focuses on delivering technologies and products that help farmers increase productivity and manage crop health. Corteva’s operations combine seed genetics, crop protection chemistries, digital tools and biological solutions to address the full cycle of crop production.

Core business activities include research and development of seed genetics and trait technologies, formulation and sale of crop protection products (such as herbicides, insecticides and fungicides), and the development of seed treatments and biologicals.